- Home
- CIIT vs ACRV Comparison
CIIT vs ACRV Comparison
Compare CIIT & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIIT
- ACRV
- Stock Information
- Founded
- CIIT N/A
- ACRV 2018
- Country
- CIIT Hong Kong
- ACRV United States
- Employees
- CIIT N/A
- ACRV N/A
- Industry
- CIIT
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- CIIT
- ACRV Health Care
- Exchange
- CIIT NYSE
- ACRV Nasdaq
- Market Cap
- CIIT 36.0M
- ACRV 40.4M
- IPO Year
- CIIT N/A
- ACRV 2022
- Fundamental
- Price
- CIIT $1.08
- ACRV $1.40
- Analyst Decision
- CIIT
- ACRV Buy
- Analyst Count
- CIIT 0
- ACRV 7
- Target Price
- CIIT N/A
- ACRV $17.60
- AVG Volume (30 Days)
- CIIT 267.1K
- ACRV 383.3K
- Earning Date
- CIIT 06-09-2025
- ACRV 08-12-2025
- Dividend Yield
- CIIT N/A
- ACRV N/A
- EPS Growth
- CIIT N/A
- ACRV N/A
- EPS
- CIIT N/A
- ACRV N/A
- Revenue
- CIIT $9,464,501.00
- ACRV N/A
- Revenue This Year
- CIIT N/A
- ACRV N/A
- Revenue Next Year
- CIIT N/A
- ACRV N/A
- P/E Ratio
- CIIT N/A
- ACRV N/A
- Revenue Growth
- CIIT 51.52
- ACRV N/A
- 52 Week Low
- CIIT $0.56
- ACRV $1.05
- 52 Week High
- CIIT $5.38
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- CIIT N/A
- ACRV 59.74
- Support Level
- CIIT N/A
- ACRV $1.23
- Resistance Level
- CIIT N/A
- ACRV $1.36
- Average True Range (ATR)
- CIIT 0.00
- ACRV 0.08
- MACD
- CIIT 0.00
- ACRV 0.01
- Stochastic Oscillator
- CIIT 0.00
- ACRV 92.59
About CIIT TIANCI INTERNATIONAL INC
Tianci International Inc along with its subsidiaries is engaged in sale of components of electronic devices, development of software and websites, technical consulting, and providing maintenance support on customized software. The company's business is predominantly carried out in Hong Kong with a substantial portion of its overall revenue being generated from its Electronic Device Hardware Components Sales segment.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.